Open Access

Kawasaki disease in Sicily: clinical description and markers of disease severity

Italian Journal of Pediatrics201642:92

DOI: 10.1186/s13052-016-0306-z

Received: 21 March 2016

Accepted: 21 October 2016

Published: 2 November 2016

Abstract

Background

Kawasaki disease (KD) is an acute systemic vasculitis of small and middle size arteries; 15-25 % of untreated patients and 5 % of patients treated with intravenous immunoglobulin (IVIG) develop coronary artery lesions (CAL). Many studies tried to find the most effective treatment in the management of resistant KD and to select the risk factors for CAL.

Our data are assessed on children from west Sicily, characterized by a genetic heterogeneity.

Methods

We studied the clinical data of 70 KD Sicilian children (36 males: 51 %; 34 females: 49 %), analysed retrospectively, including: demographic and laboratory parameters; echocardiographic findings at diagnosis, at 2, 6 and 8 weeks, and at 1 year after the onset of the illness.

Results

Forty-seven had Typical KD, three Atypical KD and twenty Incomplete KD. Age at the disease onset ranged from 0.1 to 8.9 years. IVIG were administered 5 ± 2 days after the fever started. Defervescence occurred 39 ± 26 hours after the first IVIG infusion. Fifty-six patients (80 %) received 1 dose of IVIG (responders); 14 patients (20 %) had a resistant KD, with persistent fever after the first IVIG dose (non responders). Ten (14 %) non responders responded to the second dose, 4 (5 %) responded to three doses; one needed treatment with high doses of steroids and Infliximab.

Cardiac involvement was documented in twenty-two cases (eighteen with transient dilatation/ectasia, fifteen with aneurysms). Pericardial effusion, documented in eleven, was associated with coronaritis and aneurysms, and was present earlier than coronary involvement in seven.

Hypoalbuminemia, D-dimer pre-IVIG, gamma-GT pre-IVIG showed a statistically significant direct correlation with IVIG doses, highlighting the role of these parameters as predictor markers of refractory disease. The persistence of elevated CRP, AST, ALT levels, a persistent hyponatremia and hypoalbuminemia after IVIG therapy, also had a statistical significant correlation with IVIG doses.

Non responders showed higher levels of D-dimer and gamma-GT pre-IVIG, persistent high levels of D-dimer, CRP, AST, ALT, hypoalbuminemia and hyponatremia after IVIG.

Conclusions

This is the first study on KD in Sicily. We suggest some laboratory parameters as predictive criteria for resistant KD. Patients who show early pericarditis need careful surveillance for coronary lesions.

Keywords

Kawasaki Disease Vasculitis Cardiovascular Disease Small Vessel Vasculitis

Background

Kawasaki disease (KD) is an acute systemic vasculitis, affecting small and middle size arteries, occurring mainly in infants and children up to 5 years of age [1, 2]. It is the second most common cause of vasculitis after Schönlein-Henoch Purpura and the first cause of acquired heart disease in childhood in western countries [3]. It is self-limited, with fever resolving after an average of 12 days even without treatment [1], of unknown aetiology and is characterized by a marked increase of serum levels of proinflammatory cytokines and chemokines [1] and the activation of the innate and adaptive immune system [46].

Timely administration of IVIG is fundamental to reduce inflammation of coronary artery walls and to prevent coronary damage; the long-term treatment in individuals developing coronary aneurysms must prevent myocardial ischemia and infarction [1]. About 15-25 % of untreated KD patients and approximately 5% KD patients who received intravenous immunoglobulin (IVIG) treatment may develop coronary artery lesions (CAL).

IVIG administered 10 days or more after fever onset may contribute to reduce inflammation but are usually thought to be ineffective in preventing CAL [7]. The rate of IVIG resistance is higher in patients treated before the fifth day of fever, though it is unclear whether a poor outcome follows the early treatment or if patients diagnosed with KD before the fifth day have a more severe form of the disease with a higher risk of cardiac lesions [8].

A single high dose of IVIG (2 g/kg), combined with acetylsalicylic acid, is the gold standard therapy in the acute stage of KD. However, approximately 8-38 % of children are unresponsive to initial high dose IVIG treatment and this condition is defined as “refractory KD”. These patients have an increased risk of CAL development.

Many authors tried to define risk factors of IVIG failure. Kuo et al. showed that pre-IVIG hypoalbuminemia (≤2.9 g/dL) was more common in non responders to IVIG than in good responders [9]. Kobayashi et al. defined a score system to calculate the risk of refractory KD. They indentified seven variables to generate a scoring model useful to predict IVIG resistance: days of illness at initial treatment ≤ 4, age ≤ 12 months at the onset, high serum levels of AST ≥100 IU/L, high CRP (≥10 mg/dl), elevated percentage of neutrophils (≥80 %), low serum sodium levels (≤133 mmol/L), low platelet count (≤30.0 × 104/mm3) [10]. Other authors included a lower lymphocytes count in the Kobayashi score to increase the predictive value of IVIG-resistant patients during the subacute phase [11]. However the score has not performed well in non-Japanese populations [12].

Failure of the first dose of IVIG remains the most significant risk factor for CAL. However, there are few studies on non-responders to a second dose of IVIG. A recent study reported that patients with CRP level ≥ 8mg/dl after the first dose of IVIG, have a higher risk to fail additional IVIG doses and may require further IVIG plus rescue therapy [13]. Furthermore these patients have a higher incidence of CAL with persistent lesions [13]. Other authors have recently evidenced that elevated D-dimer levels are a risk factor for CAL in patients non responder to IVIG treatment [14]. Recently, fractional change-C-reactive protein was also considered to be useful for predicting initial IVIG resistance in KD [15]. Refractory KD may require additional therapy such as a second dose of IVIG, steroids, infliximab or other biological drugs. As for corticosteroids, Ogata et al. evaluated the efficacy of steroids plus IVIG treatment for KD defined at high risk. Intravenous methylprednisolone at the dose of 30 mg/kg for three days in association with IVIG was effective to guarantee a good response and prevent CAL [16].

We aimed to describe clinical characteristics and severity factors in KD patients in Sicily and to analyze the risk factors of severe and/or refractory form of KD. Sicilian Caucasian population had origin from a miscellaneous of many populations coming from Greece, Northen Europe, Arabic countries, Spain, France, Northen Italy… They conquered this country in the course of the centuries, with complex cultural, familial and genetic interactions. These people married with local people, acquired local customs and traditions and several times maintained their residence in Sicily.

To our knowledge this is the first KD study in the island.

Methods

Patients

We analyzed the clinical data of 70 KD Sicilian children, admitted to the Paediatric Clinic of Palermo from 2008 to 2014.

Charts were analyzed retrospectively and data were collected in a customized database. Data included demographic and laboratory parameters (age, sex, days of fever at the admittance, days of fever at the start of IVIG, neutrophils, lymphocytes and platelet count, haemoglobin, albumin, ALT, AST, gamma-GT, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Na, D-dimer), as well as echocardiographic findings at diagnosis, at 2 weeks, at 6 to 8 weeks, and at 1 year after the onset of the illness.

More frequent echocardiographic evaluation was performed only in patients at high risk (children persistently febrile or with CAL, ventricular dysfunction, pericardial effusion, or valvular regurgitation).

The study has been granted from requiring ethics approval by the ethics committee. “Comitato Etico Palermo1”.

Ethics committee approval was not necessary since for anonymized data this is not required by Italian regulations.

In order to early identify non responders, after considering the Kobayashi score system and other side factors considered in the international literature, we analyzed the following parameters: age, gender, days of the disease at IVIG start, neutrophils, lymphocytes and platelet count, haemoglobin, albumin, ALT, AST, gamma-GT, CRP, ESR, Na, D-Dimer. We correlated these parameters to each other and with the days of fever at the start of the IVIG treatment, the response to IVIG, the clinical and laboratory outcome, cardiologic involvement and CAL.

Statistics

All variables were tested for normality with the Anderson-Darling normality test. All variables were expressed as mean ± standard deviation. The degree of linear relationship between clinical, microbiological and biochemical parameters was calculated using Pearson product moment correlation coefficient; statistical significance was accepted at p less than 0.05. Calculations were performed using MiniTAB release 13.1 Statistical Software.

Results

Among the 70 patients [Males: 36 (51%); Females: 34 (49%); age (mean ± SD): 2.17 ± 1.80 years] the male to female ratio of KD patients was 1:1. Forty-seven (68%) were diagnosed as typical KD, 3 (4%) as atypical KD, 20 (28%) as incomplete KD, following the definition of Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [1, 17].

At the hospitalization fever had been present for a mean of 5 ± 2 days; the most frequent signs/symptoms at diagnosis are described in Table 1. Associated findings included radiographically confirmed pneumonia in 6 patients; hepatomegaly documented by ultrasound in 44 patients, and gallbladder enlargement in 35.
Table 1

Signs/Symptoms at diagnosis

Symptoms

Number of patients

Percentage (%)

Fever

70

100

Conjunctivitis

62

86

Stomatitis

59

84

Rash

50

71

Lymphadenopathy

43

61

Extremity changes

7

10

Echocardiographic follow up showed the persistence of coronary lesions (varying from coronary brightness to aneurysms), at 6 to 8 weeks, and at 1 year after the onset of the illness in thirty-three patients (47 %): the z-score was > 4 in 15/33 patients (45 %); > 2.5 and < 4 in 18/33 children (55 %). CAL were reported in 22/47 patients (47 %) with typical KD, 2/3 patients (67 %) with atypical KD, 9/20 patients (45 %) with incomplete KD. Among the patients who developed coronary involvement, 25 (76 %) were responders, 8 (24 %) were non responders. Among the 15 patients (21 %) who developed coronary aneurysms, 12 (80 %) had typical KD; one had atypical KD; two had incomplete KD.

IVIG were administered 5.3 ± 2.4 days after the fever started. Defervescence occurred 39 ± 26 hours after the first IVIG infusion. Among the 70 patients, 56 patients (80 %) received 1 dose of IVIG (responders); 14 patients (20 %) had a resistant KD, with persistent fever after the first IVIG dose (non responders). In the group of non responders KD, 10 (14 %) responded to the second dose, 4 (5 %) responded to three doses while only one patient needed treatment with high doses of steroids and Infliximab.

Seventy-one percent (10/14) of non-responders vs 50 % (28/56) of responders showed cardiac involvement (p < 0.05). Pericarditis was present in eleven and associated with coronaritis in 7/25 (28%), with aneurysms in 5/15 (33 %), and in seven it was documented earlier than coronary involvement. The evidence of early pericarditis had a significant positive correlation with the development of aneurisms (p = 0.035; r = 0.253).

Acquired valvular insufficiency (of tricuspid and/or mitral valves) was documented in 4 patients, all in the non responder group. Valvular insufficiency had a statistically significant positive correlation with the doses of IVIG (p = 0.002; r = 0.358) and fibrinogen pre-IVIG (p = 0.048; r = 0.273).

Among the 15 patients who developed coronary aneurysms, 11 (73 %) were responders, 4 (27 %) were non responders: these received three IVIG doses.

The presence of coronary aneurysms showed a statistically significant positive correlation with IVIG doses (p = 0.026; r = 0.265), with platelet count pre-IVIG (p = 0.045; r = -0.240), AST and ALT post-IVIG (p = 0.002; r = 0.364 and p = 0.001; r = 0.390), gamma-GT post-IVIG (p = 0.030; r = 0.290), D-dimer post-IVIG (p = 0.023; r = 0.379).

The significant differences between responders and non responders are shown in Table 2.
Table 2

Clinical features and laboratory findings in responders and non responders patients

 

Responders

Non responders

P

Cardiac involvement

50 % (28/56)

71 % (10/14)

p < 0.05

Age

2.34 ± 1.92 years

2.17 ± 1.80 years

p = NS

First dose of IVIG < 5 days

5/56 (9 %)

4/14 (29 %)

p < 0.05

Hyponatraemia (< 133 mEq/L)

23/56 (41 %)

11/14 ( 79 %)

p < 0.05

D-dimer (ng/ml) pre-IVIG

818 ± 666

1342 ± 898

p < 0.05

D-dimer (ng/ml) post-IVIG

635 ± 545

1073 ± 1011

p < 0.05

Furthermore in the non responder group, 7 (50 %) were males, and 3/7 (43%) did not respond to the second dose of IVIG and received 3 doses of IVIG; 7 non responders (50 %) were females, and only one of them (14 %) did not respond to the second IVIG dose.

We applied the Kobayashi score to our patients and verified that in IVIG non responder group the score was ≥ 4 only in 8/14 patients (57 %). The Kobayashi score was ≥ 4 in 8/15 (53 %) patients who developed coronary artery aneurysms. In IVIG responders, the Kobayashi score was ≥ 4 in 8/54 (15 %).

Natraemia and albuminemia pre-IVIG were lower in non responders, however the correlation did not reach the statistical significance. On the contrary, persistent hyponatraemia and hypoalbuminemia after the first IVIG dose had a significant correlation with the number of IVIG doses, with a negative correlation of IVIG doses with natraemia and albuminemia post-IVIG (p = 0.039; r = -0.258 and p = 0.05; r = -0.243 respectively), gamma-GT pre-IVIG (p = 0.014; r = -0.314), AST post-IVIG (p = 0.016; r = -0.290), ALT post-IVIG (p = 0.000; r = -0.468), low haemoglobin levels and platelet count after the first dose of IVIG (p = 0.05; r = -0.236); it showed a positive correlation with CRP levels post-IVIG (p = 0.030; r = 0.263) and D-dimer pre-IVIG (p = 0.005; r = 0.389),. However only 4/14 (29 %) in the non responder group had low platelet count in acute phase (≤30.0 × 104/mm3).

Coronary aneurysms showed a statistically significant positive correlation with IVIG doses (p = 0.026; r = 0.265), with platelet count pre-IVIG (p = 0.045; r = -0.240), AST and ALT post-IVIG (p = 0.002; r = 0.364 and p = 0.001; r = 0.390 respectively), gamma-GT post-IVIG (p = 0.030; r = 0.290), D-dimer post-IVIG (p = 0.023; r = 0.379).

Furthermore valvular insufficiency had a significant positive correlation with fibrinogen pre-IVIG (p = 0.048; r = 0.273).

D-dimer had a statistically significant correlation with several laboratory parameters. D-dimer post-IVIG had a statistically significant negative correlation with CRP post-IVIG (p = 0.003; r = -0.475), and a positive correlation with leukocyte count post-IVIG (p = 0.004; r = 0.469) and with the percentage of neutrophils post-IVIG (p = 0.002; r = 0.493). Fibrinogen pre-IVIG had a statistically significant positive correlation with leukocytes pre-IVIG (p = 0.002; r = 0.453) and with the percentage of neutrophils pre-IVIG (p = 0.000; r = 0.496).

Discussion

The aetiology of KD remains unknown; however, epidemiologic evidence suggests the possible role of infectious agents in patients with a genetic background [18]. The incidence of cardiac involvement varies between different studies; however, it is higher in patients with refractory KD and in untreated patients (25%) [19]. In our population coronary artery aneurysms were present in 21% of patients: the majority of them were patients with typical KD. Cardiac involvement was present in 71% of non responders vs. 50% of responders, in accordance with published data [1, 3, 14].

A recent report described patients with precocious pericardial effusion and later development of CAL [20]. In our patients pericardial effusion was associated with coronaritis in 28 %, associated with aneurysms in 33%, and was documented earlier than coronary involvement, confirming previous findings.

Hepatomegaly and gallbladder enlargement were signs documented by ultrasound in 63 % and 50 % of patients, respectively. The high incidence of these complications may be explained by the routine abdominal ultrasound performed in these patients, at diagnosis and during persistence of fever and/or of increased biochemical signs of inflammation.

We tested the ability of the Kobayashi Score [10] to predict IVIG resistance and coronary artery aneurysms in our patients; however these conditions were not predicted by a high Kobayashi Score, because about 50 % of the patients were missed by the score. Other authors tested this and other scores in their populations, but did not demonstrate a diagnostic utility [2124].

In our patients hypoalbuminemia, D-dimer levels pre-IVIG and gamma-GT pre-IVIG showed a statistically significant direct correlation with IVIG doses, highlighting the role of these parameters as possible predictors of refractory KD. Furthermore, patients who show early pericarditis need more careful surveillance for CAL [20] with regard to treatment [25].

In a recent wide-scale study performed in Japan, age, sex, CRP levels, platelet count, lower albumin levels were confirmed to be linked to a higher risk of CAL [26]. In our population coronary aneurisms showed a statistically significant correlation with IVIG doses, platelet count pre-IVIG; AST, ALT, gamma-GT post-IVIG; D-dimer post-IVIG. These data confirm a link between coronary vasculitis and the severity of systemic vascular inflammation and/or extra-cardiac involvement.

Our center is one of the three major pediatric hospitals in Sicily were children affected by Kawasaki disease are treated. However we have not yet the epidemiological data about the real incidence of Kawasaki disease in our region.

A recent study evaluated epidemiology of KD in central Italy: the peak of incidence was in the second year of life, with a mild prevalence of males. The icidence was 17.6:100.000 children under five years. 5.2 % had one or more cardiac complications, 2.6 % had CAL [27].

Conclusion

In conclusion, this is the first study on KD in Sicily: we described the clinical data and evaluated the correlation of clinical and biochemical data with the response to IVIG in a genetically heterogeneous population. History reveals that Sicily was the theatre of different dominations (from Phoenicians to Greeks, Romans, Arabs, Normans, Bourbons): these populations leaved in the island art, culture and a complex genetic imprinting whose influence is still alive.

Declarations

Acknowledgement

Not applicable.

Funding

The authors declare that they have no funding for the research reported.

Authors’ contributions

MCM participated in the design of the study and performed the statistical analysis. GC participated in its design. EP collected patients’ data. RC participated in the coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

The clinical database is not publicly available since it contains clinical data and this would be against our privacy policy.

Ethics approval and consent to participate

Not applicable (not needed as per local regulations since data were anonimyzed and extracted retrospectively from clinical charts).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
University Department Pro.Sa.M.I. “G. D’Alessandro”, University of Palermo
(2)
NEUROFARBA Department University of Florence, and AOU Meyer

References

  1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–71. doi:10.1161/01.CIR.0000145143.19711.78.View ArticlePubMedGoogle Scholar
  2. Cimaz R, Falcini F. An update on Kawasaki disease. Autoimmun Rev. 2003;2(5):258–63.View ArticlePubMedGoogle Scholar
  3. Sundel RP. Kawasaki Disease. Rheum Dis Clin North Am. 2015;41(1):63–73. doi:10.1016/j.rdc.2014.09.010.View ArticlePubMedGoogle Scholar
  4. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet. 2003;361:1270–2. http://dx.doi.org/10.1016/S0140-6736(03)12986-8.View ArticlePubMedGoogle Scholar
  5. Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW, Sundel RP, Brown PO, Burns JC, Relman DA. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007;8:R261. doi:10.1186/gb-2007-8-12-r261.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Ikeda K, Yamaguchi K, Tanaka T, Mizuno Y, Hijikata A, Ohara O, Takada H, Kusuhara K, Hara T. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol. 2010;160:246–55. doi:10.1111/j.1365-2249.2009.04073.x.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012;129(2):e291–7. doi:10.1542/peds.2011-1704.View ArticlePubMedGoogle Scholar
  8. Kuo H-C, Yang KD, Chang W-C, Ger L-P, Hsieh K-S. Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 2012;53(1):4–11. doi:10.1016/j.pedneo.2011.11.003.View ArticlePubMedGoogle Scholar
  9. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr. 2010;99(10):1578–83. doi:10.1111/j.1651-2227.2010.01875.x.View ArticlePubMedGoogle Scholar
  10. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12. doi:10.1161/CIRCULATIONAHA.105.592865.View ArticlePubMedGoogle Scholar
  11. Do YS, Kim KW, Chun JK, Cha BH, Namgoong MK, Lee HY. Predicting factors for refractory kawasaki disease. Korean Circ J. 2010;40(5):239–42. doi:10.4070/kcj.2010.40.5.239.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities. Am J Ther. 2015 [Epub ahead of print]
  13. Iwashima S, Kimura M, Ishikawa T, Ohzeki T. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study. Clin Drug Investig. 2011;31(3):191–9. doi:10.2165/11538910-000000000-00000.View ArticlePubMedGoogle Scholar
  14. Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S. Elevated d-Dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease. Ther Apher Dial. 2015;19(2):171–7. doi:10.1111/1744-9987.12235.View ArticlePubMedGoogle Scholar
  15. Lee SM, Lee JB, Go YB, Song HY, Lee BJ, Kwak JH. Prediction of resistance to standard intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J. 2014;44(6):415–22. doi:10.4070/kcj.2014.44.6.415.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129(1):e17–23. doi:10.1542/peds.2011-0148.View ArticlePubMedGoogle Scholar
  17. Cimaz R, Sundel R. Atypical and incomplete Kawasaki disease. Best Prac Res Clin Rheum. 2009;23:689–97.View ArticleGoogle Scholar
  18. Khor CC, Davila S, Breunis WB, Lee YC, Shimizu C, Wright VJ, Yeung RS, Tan DE, Sim KS, Wang JJ, Wong TY, Pang J, Mitchell P, Cimaz R, Dahdah N, Cheung YF, Huang GY, Yang W, Park IS, Lee JK, Wu JY, Levin M, Burns JC, Burgner D, Kuijpers TW, Hibberd ML, Hong Kong–Shanghai Kawasaki Disease Genetics Consortium; Korean Kawasaki Disease Genetics Consortium; Taiwan Kawasaki Disease Genetics Consortium; International Kawasaki Disease Genetics Consortium; US Kawasaki Disease Genetics Consortium. Blue Mountains Eye Study. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011;43(12):1241–6.View ArticlePubMedGoogle Scholar
  19. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–85. doi:10.1161/01.CIR.94.6.1379.View ArticlePubMedGoogle Scholar
  20. Lega JC, Bozio A, Cimaz R, Veyrier M, Floret D, Ducreux C, Reix P, Di Filippo S. Extracoronary echocardiographic findings as predictors of coronary artery lesions in the initial phase of Kawasaki disease. Arch Dis Child. 2013;98(2):97–102. doi:10.1136/archdischild-2011-301256.View ArticlePubMedGoogle Scholar
  21. Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities. (Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E) Am J Ther 2015 [Epub ahead of print]
  22. Choo KH, Kang SJ. Clinically useful predictors of resistance to intravenous immunoglobulins and prognosis of coronary artery lesions in patients with incomplete Kawasaki disease. Korean Circ J. 2014;44(5):328–35. doi:10.4070/kcj.2014.44.5.328.View ArticleGoogle Scholar
  23. Kanamitsu K, Kakimoto H, Shimada A, Nakata Y, Ochi H, Watanabe H, Iwasaki Y, Tokorodani C, Kanazawa A, Maruyama H, Miyazawa M, Nishiuchi R, Kikkawa K. Verification of risk scores to predict intravenous immunoglobulin resistance in incomplete Kawasaki disease. Pediatr Int. 2015. [Epub ahead of print]
  24. Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015;100(4):366–8. doi:10.1136/archdischild-2014-307397. Epub 2015 Feb 10.View ArticlePubMedGoogle Scholar
  25. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20. doi:10.1016/S0140-6736(11)61930-2.View ArticlePubMedGoogle Scholar
  26. Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Nakamura Y, Yanagawa H, Kawasaki T. Cardiac lesions and initial laboratory data in Kawasaki Disease: a nationwide survey in Japan. J Epidemiol. 2015;25(3):189–93. doi:10.2188/jea.JE20140128.View ArticlePubMedGoogle Scholar
  27. Mauro A, Fabi M, Da Frè M, Guastaroba P, Corinaldesi E, Calabri GB, Giani T, Simonini G, Rusconi F, Cimaz R. Kawasaki Disease: an epidemiological study in central Italy. Pediatr Rheumatol Onlin J. 2016;14(1):22. doi:10.1186/s12969-016-0084-6.View ArticleGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement